CALL/MODERNA/120/0.1/21.06.24 | Real-time BOERSE MUENCHEN 03:55:40 20/06/2024 pm IST | ||
| 1.17 EUR | +4.46% |
|
| Current month | -47.42% | ||
| 1 month | -20.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 1.17 | +4.46% |
| 19/24/19 | 1.12 | -15.15% |
| 18/24/18 | 1.32 | -29.41% |
| 17/24/17 | 1.87 | +4.47% |
| 14/24/14 | 1.79 | -27.53% |
Real-time BOERSE MUENCHEN
Last update June 20, 2024 at 03:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Goldman Sachs |
| WKN | GZ9BGQ |
| ISIN | DE000GZ9BGQ4 |
| Date issued | 27/02/2023 |
| Strike | 120 $ |
| Maturity | 21/06/2024 (2 Days) |
| Parity | 10 : 1 |
| Emission price | 4.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.74 € |
|---|---|
| Lowest since issue | 0.213 € |
| Spread | 0.15 € |
| Spread % | 11.28% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Warrants
- Warrant
